Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Guilhot F, et al. Among authors: mercier m. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483613 Clinical Trial.
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E. Cornillon J, et al. Among authors: mercier m. Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20. Ann Hematol. 2019. PMID: 31111177
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
Tondeur S, Paul F, Riou J, Mansier O, Ranta D, Le Clech L, Lippert E, Tavitian S, Chaoui D, Mercier M, De Renzis B, Cottin L, Cassinat B, Chrétien JM, Ianotto JC, Allangba O, Marzac C, Voillat L, Boyer F, Orvain C, Hunault-Berger M, Girodon F, Kiladjian JJ, Ugo V, Luque Paz D. Tondeur S, et al. Among authors: mercier m. Leukemia. 2021 Mar;35(3):871-875. doi: 10.1038/s41375-020-0991-x. Epub 2020 Jul 21. Leukemia. 2021. PMID: 32694617 No abstract available.
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Le Bourgeois A, et al. Among authors: mercier m. Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274. Ann Oncol. 2017. PMID: 28911060 Free article.
Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS. Garciaz S, et al. Among authors: mercier m. Leuk Lymphoma. 2019 Nov;60(11):2802-2805. doi: 10.1080/10428194.2019.1599112. Epub 2019 Apr 24. Leuk Lymphoma. 2019. PMID: 31014144 No abstract available.
Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.
Augeul-Meunier K, Chretien ML, Stoppa AM, Karlin L, Benboubker L, Diaz JMT, Mohty M, Yakoub-Agha I, Bay JO, Perrot A, Bulabois CE, Huynh A, Mercier M, Frenzel L, Avet-Loiseau H, de Latour RP, Cornillon J. Augeul-Meunier K, et al. Among authors: mercier m. Bone Marrow Transplant. 2018 Jun;53(6):749-755. doi: 10.1038/s41409-018-0122-8. Epub 2018 Mar 9. Bone Marrow Transplant. 2018. PMID: 29523884
Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).
Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, Huynh A, Mercier M, Bulabois CE, Lioure B, Chantepie S, Beguin Y, Bourhis JH, Malfuson JV, Clément L, Peffault de la Tour R, Cornillon J. Fayard A, et al. Among authors: mercier m. Bone Marrow Transplant. 2019 Oct;54(10):1586-1594. doi: 10.1038/s41409-019-0475-7. Epub 2019 Feb 15. Bone Marrow Transplant. 2019. PMID: 30770870 Free article.
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G. Tout M, et al. Among authors: mercier m. Blood. 2017 May 11;129(19):2616-2623. doi: 10.1182/blood-2016-10-744292. Epub 2017 Mar 1. Blood. 2017. PMID: 28251914 Free article. Clinical Trial.
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D. Tout M, et al. Among authors: mercier m. Clin Pharmacokinet. 2017 Jun;56(6):635-647. doi: 10.1007/s40262-016-0470-8. Clin Pharmacokinet. 2017. PMID: 27783363 Free article. Clinical Trial.
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N. Decroocq J, et al. Among authors: mercier m. Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8. Am J Hematol. 2018. PMID: 29226497 Free article.
546 results